Picture of Cytek Biosciences logo

CTKB — Cytek Biosciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Cytek Biosciences Q3 revenue rises 2% on US growth

Cytek Biosciences Q3 revenue rises 2% on US growth


Overview

  • Cell analysis solutions firm's Q3 revenue rose 2% yr/yr

  • Company's Q3 gross margin improved by nearly 600 basis points yr/yr

  • Company maintained midpoint of 2026 revenue guidance, narrowing the range


Outlook

  • Cytek Biosciences sees 2026 revenue between $208 mln and $211 mln

  • Company expects a strong finish to 2026 and continued market share gains


Result Drivers

  • US GROWTH AND HIGH-END INSTRUMENT DEMAND - Co said Q3 revenue growth was led by the U.S. market, with strong demand for high-end instruments and continued growth in service

  • RECURRING REVENUE - Co said recurring revenue from service and reagents increased, making up a larger share of total revenue

  • GROSS MARGIN EXPANSION - Co reported higher gross margin, citing improved product and service mix


Company press release: ID:nGNX54gTvF


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$53.23 mln

$52.80 mln (2 Analysts)

Q3 Net Loss

$6.10 mln

Q3 Adjusted EBITDA

$711,000

Q3 Pretax Loss

$6.91 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Reuters Recommended Reads

  • Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

  • Nov 3 - Revvity Q3 revenue beats estimates, raises FY guidance

  • Nov 3 - SOPHiA GENETICS Q3 revenue rises on US market strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Cytek Biosciences

See all news